Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis.

Abstract

Despite the introduction of JAK inhibitors, allogeneic hematopoietic cell transplant remains the only potentially curative treatment for patients with myelofibrosis but has considerable treatment-related complications.

Whether the incorporation of JAK inhibition into the transplant algorithm leads to improved outcomes is still unclear.

Here, we analyzed different transplant platforms in myelofibrosis patients undergoing a first transplant, comparing immune profiles and outcomes of (1) 33 patients continuing JAK inhibition at start of conditioning until stable engraftment (PERI-group), (2) 38 patients receiving JAK inhibition prior to transplant until start of conditioning (PRE-group), and (3) 38 patients that had never received JAK inhibition (NON-group).

Patients in the PERI-group showed significantly higher early B-cell recovery as well as significantly increased late recovery of gamma-delta T cells and NK cells.

We observed excellent neutrophil and platelet engraftment (100% for both) in the PERI-group and no hematotoxic effects or increased rates of infections following peri-transplant JAK inhibition.

Cumulative incidence of acute graft-versus-host disease (GvHD) grade II-IV at day 100 after transplant was 15% in the PERI-group versus 29% in the PRE-group versus 34% in the NON-group.

Cumulative incidence of relapse at 1 year after transplant was 9% in the PERI-group compared with 16% in the PRE-group and 18% in the NON-group. In conclusion, peri-transplant JAK inhibition was feasible with promising engraftment and acute GvHD rates, though deserves further investigation.

References:

D. Tremblay and J. Mascarenhas, “Pharmacotherapeutic Advances for Splenomegaly in Myelofibrosis,” Expert Opinion on Pharmacotherapy 24, no. 5 (2023): 577–585, https://doi.org/10.1080/14656566.2023.2192350.
A. T. Gerds, S. Verstovsek, A. M. Vannucchi, et al., “Momelotinib Versus Danazol in Symptomatic Patients With Anaemia and Myelofibrosis Previously Treated With a JAK Inhibitor (MOMENTUM): An Updated Analysis of an International, Double‐Blind, Randomised Phase 3 Study,” Lancet Haematology 10, no. 9 (2023): e735–e746, https://doi.org/10.1016/S2352‐3026(23)00174‐6.
C. N. Harrison, N. Schaap, A. M. Vannucchi, et al., “Janus Kinase‐2 Inhibitor Fedratinib in Patients With Myelofibrosis Previously Treated With Ruxolitinib (JAKARTA‐2): A Single‐Arm, Open‐Label, Non‐Randomised, Phase 2, Multicentre Study,” Lancet Haematology 4, no. 7 (2017): e317–e324, https://doi.org/10.1016/S2352‐3026(17)30088‐1.
C. Harrison, J. J. Kiladjian, H. K. Al‐Ali, et al., “JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis,” New England Journal of Medicine 366, no. 9 (2012): 787–798, https://doi.org/10.1056/NEJMoa1110556.
N. Pemmaraju, S. Verstovsek, R. Mesa, et al., “Defining Disease Modification in Myelofibrosis in the Era of Targeted Therapy,” Cancer 128, no. 13 (2022): 2420–2432, https://doi.org/10.1002/cncr.34205.

Article info

Journal issue:

Volume: not provided
Issue: not provided

Doi:

10.1002/ajh.27529

More resources:

Wiley

Full Text Sources

Paid